GABA-modulating pharmacotherapies show inconsistent results for improving symptoms in autism spectrum disorder
New data shows mixed results for medications targeting autism symptoms
This meta-analysis evaluated the impact of bumetanide, arbaclofen, and valproate on various symptom domains in individuals with autism spect…
Research into three specific drugs for autism shows some initial signs of improvement, but the evidence is currently too inconsistent to be …
Cannabidiol is associated with 49.9% seizure reduction in patients with Developmental and Epileptic Encephalopathies
Cannabidiol shows significant seizure reduction in some DEE patients
This meta-analysis of 2592 individuals with Developmental and Epileptic Encephalopathies (DEEs) found that pharmaceutical-grade cannabidiol …
Pharmaceutical-grade cannabidiol may help nearly half of people with certain severe epilepsy syndromes reduce their seizures by at least 50 …
Systematic review and meta-analysis of mood stabilizers for nonsuicidal self-injury in adolescents
Mood stabilizers show promise for teen self-injury and depression in China
This systematic review and meta-analysis examined nine studies from China involving adolescent patients with nonsuicidal self-injury. The au…
A review of nine studies suggests mood stabilizers may help reduce self-injury and depression in Chinese adolescents, offering new options f…
Predictive nomogram identifies suboptimal valproate concentrations in pediatric epilepsy patients using daily dose, organ injury, and meropenem
New tool predicts dangerous valproate levels in children with epilepsy
This retrospective cohort study of 121 pediatric patients with epilepsy aged 2–18 years developed a predictive nomogram to identify suboptim…
A new calculator can flag children with epilepsy who are likely to get unsafe valproate levels, helping doctors adjust doses before problems…
FDA Approves Valproic Acid Oral Solution (valproic acid) for Complex Partial and Absence Seizures
The FDA has approved a liquid form of an older seizure medicine called valproic acid
Valproic acid oral solution is approved as monotherapy and adjunctive therapy for complex partial seizures and for simple and complex absenc…
The FDA approved a liquid version of valproic acid to help adults and children over 10 manage complex partial and absence seizures when pill…
FDA Approves Valproic Acid Oral Solution (valproic acid) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures
FDA approves a liquid form of an existing epilepsy medicine called valproic acid
The FDA has approved valproic acid oral solution for monotherapy and adjunctive therapy of complex partial seizures, and as sole and adjunct…
FDA approves liquid valproic acid for epilepsy patients 10 and older who struggle to swallow pills or need flexible dosing.
FDA Approves Valproic Acid Oral Solution (valproic acid) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures
The FDA has approved a liquid form of an existing epilepsy and migraine prevention medicine
The FDA has approved valproic acid oral solution for monotherapy and adjunctive therapy of complex partial seizures, and as sole and adjunct…
The FDA approved a liquid version of valproic acid, an established epilepsy and migraine medicine, offering an easier swallowing option for …
FDA Approves Depakote (divalproex sodium) for Manic Episodes Associated with Bipolar Disorder
FDA approves Depakote for treating manic episodes in bipolar disorder
The FDA approved Depakote (divalproex sodium) for the treatment of manic episodes associated with bipolar disorder.
FDA approves Depakote for treating manic episodes in hospitalized adults with bipolar disorder, offering doctors a new option for managing a…
FDA Approves Depakote ER (divalproex sodium) for Acute Manic or Mixed Episodes in Bipolar Disorder
FDA approves a new once-daily pill for treating manic episodes in bipolar disorder
The FDA has approved Depakote ER, an extended-release valproate, for the acute treatment of manic or mixed episodes associated with bipolar …
FDA approves a new once-daily pill for short-term treatment of severe manic episodes in adults with bipolar I disorder.
FDA Approves Valproate Sodium Injection (valproate sodium) for IV Use in Complex Partial and Absence Seizures
FDA approves an injectable version of an existing seizure medicine for short-term use
The FDA approved Valproate Sodium Injection as an intravenous alternative when oral valproate is temporarily not feasible.
FDA approves an injectable seizure medicine for short-term use when patients can't swallow pills due to surgery or stomach issues.
FDA Approves Depakote Sprinkle Capsules (valproate) for Monotherapy and Adjunctive Therapy of Complex Partial and Absence Seizures
FDA approves a new sprinkle capsule form of the epilepsy drug Depakote
The FDA approved Depakote Sprinkle Capsules (valproate) for monotherapy and adjunctive therapy of complex partial seizures and simple and co…
FDA approves a sprinkle capsule form of Depakote that patients can open and mix with soft food to help those who struggle to swallow pills.